HomeAI · summaries
Storia in 2 fonti
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA grants priority review to Enspryng for thyroid eye disease
The FDA granted priority review to a supplemental biologics license application for Enspryng for thyroid eye disease, according to a press release from Genentech. Enspryng…
- ·
morningstar.com
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid…
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)